Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Aetna Inc    AET

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Goldman M&A head Sykes joins management committee

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2012 | 11:07pm CET

Gene Sykes, global head of Goldman Sachs Group Inc's (>> Goldman Sachs Group, Inc.) mergers and acquisitions business, has been named to the investment bank's management committee, according to an internal memo.

Gene Sykes, global head of Goldman Sachs Group Inc's (>> Goldman Sachs Group, Inc.) mergers and acquisitions business, has been named to the investment bank's management committee, according to an internal memo.

The 54-year-old investment banker joins 28 other executives on the powerful committee, which includes Chief Executive Lloyd Blankfein and Chief Operating Officer Gary Cohn, and influences decisions about Goldman's business strategy and operations.

Sykes' appointment comes just nine days after the departure of another prominent Goldman banker, Yoel Zaoui, was announced in a separate internal memo. Zaoui shared the title of M&A co-head with Sykes and had also been on the management committee.

Sykes, who is based in Los Angeles, is also chairman of the global technology, media and telecommunications department of the investment banking division. He is a member of Goldman's internal Business Standards Committee.

The Goldman veteran joined the firm in 1984 and became a partner in 1992. He has advised on several high-profile deals, including Walt Disney Co's (>> The Walt Disney Company) acquisition of Pixar, Aetna Inc's (>> Aetna Inc.) acquisition of U.S. Healthcare and Roche Holding AG acquisition of Genentech.

"Gene has played a vital role in strengthening our investment banking franchise, particularly with respect to many of the most significant companies in technology and media," Blankfein and Cohn said in the memo, whose contents were confirmed by a spokesman.

(Reporting By Lauren Tara LaCapra in New York; editing by Andre Grenon)

By Lauren Tara LaCapra

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AETNA INC
02/17 Khang & Khang LLP Announces Securities Class Action Lawsuit against Aetna Inc..
02/17 AETNA INC : Khang & Khang LLP Announces Securities Class Action Lawsuit against ..
02/17 AETNA : PA/ Management's Discussion and Analysis of Financial Condition and Resu..
02/17DJAETNA : Doubles Dividend, Boosts Stock Buyback Plans
02/17 AETNA : fattens shareholder payout after Humana deal fails
02/17 AETNA : Board of Directors Doubles Quarterly Cash Dividend, Authorizes Additiona..
02/17 Lundin Law PC Announces Securities Class Action Lawsuit against Aetna Inc. an..
02/17 AETNA INC : Lundin Law PC Announces Securities Class Action Lawsuit against Aetn..
02/16 AETNA CEO : Obamacare In A 'Death Spiral' Heading Into 2018
02/16 AETNA INC : Khang & Khang LLP Announces Securities Class Action Lawsuit against ..
More news
Sector news : Managed Healthcare - NEC
02/17DJAETNA : Doubles Dividend, Boosts Stock Buyback Plans
02/16DJCIGNA : Court Issues Temporary Order Keeping Cigna From Terminating Merger With ..
02/16DJANTHEM : Countersues After Cigna Ends Deal -- WSJ
02/15DJHUMANA : Withdrawal From Health Exchanges Pressures GOP -- Update
02/15DJHUMANA : Decision to Pull Out of Health Exchanges Pressures Republicans
More sector news : Managed Healthcare - NEC
News from SeekingAlpha
02/17 Aetna declares $0.50 dividend
02/17 Aetna authorizes $4B repurchase, declares $0.50 per share quarterly dividend
02/15 Trump administration proposes changes to ACA to reduce sign-ups by sick peopl..
02/15 Warren Buffett Reveals New Picks - Apple, Airlines, And Arb
02/15 BIOTECH FORUM DAILY DIGEST : Bristol-Myers On The Block? Biotech Continues To Ro..
Advertisement
Financials ($)
Sales 2017 60 289 M
EBIT 2017 4 682 M
Net income 2017 2 353 M
Debt 2017 2 991 M
Yield 2017 0,82%
P/E ratio 2017 18,66
P/E ratio 2018 13,78
Capi. / Sales 2017 0,78x
Capi. / Sales 2018 0,69x
Capitalization 43 957 M
More Financials
Chart AETNA INC
Duration : Period :
Aetna Inc Technical Analysis Chart | AET | US00817Y1082 | 4-Traders
Full-screen chart
Technical analysis trends AETNA INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 140 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark T. Bertolini Chairman & Chief Executive Officer
Karen S. Lynch President
Margaret M. McCarthy Executive Vice President-Operations & Technology
Shawn M. Guertin CFO, Executive VP & Chief Enterprise Risk Officer
Harold L. Paz Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AETNA INC1.02%43 957
UNITEDHEALTH GROUP INC-1.51%149 923
ANTHEM INC11.46%42 216
CIGNA CORPORATION7.62%36 857
HUMANA INC0.28%30 506
CENTENE CORP19.64%11 623
More Results